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Abstract. The aberrant activation of hedgehog (HH) signaling 
is a leading cause of the development of medulloblastoma, a 
pediatric tumor of the cerebellum. The FDA-approved HH 
inhibitor, Vismodegib, which targets the transmembrane 
transducer SMO, has shown limited efficacy in patients with 
medulloblastoma, due to compensatory mechanisms that 
maintain an active HH-GLI signaling status. Thus, the iden-
tification of novel actionable mechanisms, directly affecting 
the activity of the HH‑regulated GLI transcription factors is an 
important goal for these malignancies. In this study, using gene 
expression and reporter assays, combined with biochemical 
and cellular analyses, we demonstrate that mitogen‑activated 
kinase kinase kinase 1 (MEKK1), the most upstream kinase of 
the mitogen‑activated protein kinase (MAPK) phosphorylation 
modules, suppresses HH signaling by associating and phos-
phorylating GLI1, the most potent HH‑regulated transcription 
factor. Phosphorylation occurred at multiple residues in the 
C‑terminal region of GLI1 and was followed by an increased 
association with the cytoplasmic proteins 14‑3‑3. Of note, the 
enforced expression of MEKK1 or the exposure of medullo-
blastoma cells to the MEKK1 activator, Nocodazole, resulted 
in a marked inhibitory effect on GLI1 activity and tumor 
cell proliferation and viability. Taken together, the results of 
this study shed light on a novel regulatory mechanism of HH 
signaling, with potentially relevant implications in cancer 
therapy.
Introduction
The Sonic hedgehog (SHH) pathway regulates postnatal cerebellar 
development and its aberrant activation causes SHH-dependent 
medulloblastoma (SHH-MB), an aggressive pediatric cerebellar 
tumor (1). Hedgehog signaling is activated by the interaction of 
the HH ligand with the inhibitory receptor patched (PTCH). This 
allows the activation of the transmembrane transducer smooth-
ened (SMO), which primes a signaling cascade that involves 
changes in the interactions between the cytoplasmic transducer 
SUFU and the GLI transcription factors: GLI1, GLI2 and GLI3. 
GLI1 and GLI2 act as activators, while GLI3 is a suppressor of 
hedgehog (HH)-dependent transcription (2).
GLI1 is the most potent activator, and plays a key role in 
tumorigenesis (3). Mutations typically found in SHH‑MB include 
loss of function mutations of PTCH or SUFU or activating 
mutations of SMO or GLI2 amplifications (4). Tumors carrying 
PTCH or SMO mutations are eligible to be treated with the 
drug, Vismodegib, an FDA-approved SMO inhibitor. However, 
despite the initial positive response, these tumors promptly 
develop compensatory mechanisms (i.e., SMO mutations or 
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the activation of collateral pathways) that restore HH signaling 
to the post-receptor level (5). Furthermore, Vismodegib is not 
effective in tumors carrying genetic alterations of SUFU or 
GLI, thus implying that the identification of molecules with the 
ability to block the signaling at the post‑receptor level, i.e., at the 
GLI level, would be a preferable choice. In this regard, different 
inhibitors have been characterized to date, some directly 
targeting GLI, others targeting GLI modifiers (6).
GLI transcription factors are finely regulated at the 
post‑translational level by various modifications, such as 
phosphorylation (7), ubiquitination (8), acetylation (9,10) and 
SUMOylation (11). It has previously been demonstrated that 
targeting some of these GLI modifications may prove to be 
an additional avenue with which to inhibit HH-regulated tran-
scriptional output (12). For instance, we have previously found 
that the pharmacological induction of GLI1 acetylation, using 
selective HDAC inhibitors, efficiently turns off HH signaling, 
counteracts tumor growth and improves survival in preclinical 
models of HH‑dependent tumors (13).
Phosphorylation is another key modification that plays 
a relevant role in the regulation of GLI function. Indeed, 
phosphorylation regulates proteolytic cleavage, stability, 
compartmentalization and the activity of GLI, which in most 
cases are followed by transcriptional repression (3). Hence, 
drugs targeting specific kinases may be used as alternative 
tools to prevent GLI function in medulloblastoma and other 
HH-driven malignancies. In this context, our group and others 
have found that human GLI1 is a substrate for the energy sensor 
AMP kinase at serine 408 (Ser408) and that this modification 
destabilizes GLI1 and reduces tumor formation (14,15), thus 
implying that AMPK agonists may be used to restrain SHH‑MB 
growth. However, since Ser408 is conserved only in primates, 
preclinical studies using these compounds to test their efficacy 
in relevant animal models of medulloblastoma are unfortunately 
not feasible.
In a recent study, it was shown that also the mitogen‑acti-
vated kinase kinase kinase 2 and 3, two members of the 
most upstream mitogen-activated protein kinase (MAPK) 
phosphorylation modules, phosphorylate and inhibit 
GLI1 and medulloblastoma growth (16). In this study, we 
investigated the role of another key member of the same 
phosphorylation module, the mitogen‑activated kinase 
kinase kinase 1 (MEKK1) (17), in HH‑dependent function 
and tumorigenesis. We demonstrate that MEKK1 binds and 
phosphorylates GLI1 at multiple residues, thus causing the 
inhibition of HH/Gli1 signaling and reducing HH-dependent 
medulloblastoma cell growth.
Materials and methods
Plasmids and reagents. The pcDNA3 MEKK1 WT, pcDNA3 
MEKK1 KD plasmids were a gift from Dr G. Johnson 
(Addgene plasmid #12180); 8xGLI‑Luc was provided by the 
H. Sasaki Laboratory, RIKEN Center for Developmental 
Biology, Kobe, Japan; 12xGLI‑Luc, TK‑Renilla, P1A WT-Luc 
and P1A Mut-Luc were from Dr R. Tofgard, Karolinska 
Institute, Stockholm, Sweden; FlagGLI2 was a gift from 
Dr A. Dlugosz, University of Michigan, Ann Arbor, MI, 
USA (18); pcDNA3 FlagGLI1, pcDNA3 FlagGLI1(424‑1106), 
pcDNA3 FlagGLI1(2‑413), pcDNA3 GLI1(2‑413)Vp16, 
Gal4GLI1(424‑1106) and the 5xGal‑Luc reporters were as 
previously described in the study by Canettieri et al (9).
The pcDNA3 His‑MLK3, CMV sport6‑TAK1, CMV 
sport6‑ASK1, pcDNA3TPL2 plasmids were provided by 
Dr U. Jhala, University of San Diego, San Diego, CA, USA. Sag 
was purchased from Adipogen Life Sciences (Liestal, Basel, 
Switzerland). Nocodazole was purchased from Sigma-Aldrich, 
St. Louis, MO, USA (cat. no. M1404) and calf intestinal alka-
line phosphatase was purchased from New England Biolabs 
(cat. no. M0290S), Ipswich, MA, USA.
Cell culture and treatments. The NIH3T3 and 293T cell 
lines (cat. no. RL‑1658 and cat. no. CRL‑3216, respectively) 
were purchased from ATCC (Manassas, VA, USA) and were 
cultured and maintained according to the manufacturer's 
recommendations; the Med1‑MB cells (19), a mouse medul-
loblastoma cell line of the SHH subgroup (SHH-MB) were 
generated in the Laboratory of Dr Matthew Scott (Standford 
University, Standford, CA, USA) from patched PTCH+/-;LacZ 
mouse and were cultured and maintained as previously 
described (13,19,20). For Sag treatment, the NIH3T3 cells 
were incubated in 0.5% of fetal bovine serum, overnight, to 
allow a full HH response and were then exposed to 200 nM 
Sag for the indicated periods of time (24 h Fig. 3B, 36 h and 
48 h Fig. 4B). For Nocodazole treatments, the cells were incu-
bated with 1 µg/ml Nocodazole or the vehicle control (DMSO 
for the indicated periods of time (24 h Fig. 4A; 36 h and 48 h 
Fig. 4B, 48 h Fig. 9C).
Luciferase/Renilla assays. The 293T or NIH3T3 cells were 
transfected with the plasmids indicated in the figures, using 
Lipofectamine 2000 reagent or Lipofectamine and Plus 
reagent (Invitrogen/Thermo Fisher Scientific, Waltham, 
MA, USA) respectively, according to the manufacturer's 
recommendations. After 24 h (Figs. 1, 2B, 3A and 6A) or 48 h 
(Fig. 4A) from transfection Luciferase/Renilla assays were 
performed as previously described (9,21).
RNA analysis and reverse transcription-quantitative PCR 
(RT-qPCR). The NIH3T3 or 293T cells were treated with Sag 
or transfected with pcDNA3, pcDNA3 Flag GLI1, pcDNA3 
MEKK1, pcDNA3 MEKK1 KD, as indicated in the figures, 
and RNA was then extracted using TRIzol reagent. Reverse 
transcription was performed using the SensiFAST cDNA 
Syntesis kit (cat. no. BIO‑65054) and qPCR was performed as 
previously described (9,22), using SYBR‑Green reagent 
SensiFAST (cat. no. BIO‑94020) (both from Bioline, Memphis, 
TN, USA). Each amplification reaction was performed in trip-
licate and the average of the three threshold cycles was used to 
calculate the amount of transcript in the sample (using 
ViiA™ 7 software; Life Technologies/Thermo Fisher 
Scientific). The results were expressed as the fold induction 
relative to the control samples using the ΔΔCt method (23) as 
previously described (6). HPRT or GAPDH were used where 
indicated as endogenous controls. The thermocycling condi-
tions used for the PCR were as follows: 95˚C, 2 min; (95˚C, 
5 sec; 60˚C, 15 sec) 40 cycles SYBR‑Green oligos used are 
listed below: hGLI1 forward, GGTGGTTCACATGCGCAG 
and reverse, GGTGCGTCTTC AGGTTTTGC; hPTCH 
forward, TAGGAGTGGAGTTC ACCGTT and reverse, 
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ATCCAGGACGGGTGCAAACAT; hHPRT  forward, 
GAAGAGCTATTGTAATGACCAGTC and reverse, 
CAAGCTTGCGACCTTGACCATC; mGli1  forward, 
AAGCCAACTTTATGTCAGGG and reverse, AGAGCCCGC 
TTCTTTCTTAA; mHprt forward, GCTTCCTCCTCAGAC 
CGCTT and reverse, GGTCATAACCTGGTTCATCATC; 
and mGapdh forward, GACGGCCGCATCTTCTTGT and 
reverse, CCTGGTGACCAGGCGC.
Immunoprecipitation, western blot analysis and antibodies. 
The 293T cells were lysed with RIPA buffer (0.5% sodium-
dehoxycolate, 50 mM Tris HCl pH 7.6, 1% NP‑40, 0.1% SDS, 
140 mM NaCl and 5 mM EDTA pH 8), supplemented with 
protease and phosphatase inhibitors (5 mM sodium pyro-
phosphate, 1 mm b‑glycero phosphate and 1 mM sodium 
orthovanadate). Immunoprecipitation was performed by incu-
bation for 2 h in 1 mg of lysate with anti‑Flag M2 Affinity 
Gel (cat. no. A2220, IP 30 µl; Sigma‑Aldrich). Proteins were 
eluted and analyzed by SDS‑PAGE (polyacrylamide percent-
ages: 6% Fig. 5; 12% Fig. 6B; 10% Fig. 8B), blotted onto a 
nitrocellulose membrane (Perkin-Elmer, Waltham, MA, USA). 
The membranes were blocked in 5% milk in Tris‑buffered 
saline with 0.1% Tween‑20, and incubated overnight at 4˚C 
with the primary antibodies. The following antibodies were 
used: anti‑Flag M2 (1:1,000; cat. no. A8592; Sigma‑Aldrich), 
anti‑phosphoserine (1:500; cat. no. 16‑455; Millipore, Billerica, 
MA, USA), anti‑14‑3‑3ε (1:1,000; cat. no. sc‑1020), anti‑MEKK1 
(1:1,000; cat. no. sc‑449) (both from Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA), anti‑GLI1 (1:1,000; cat. no. 2553S; 
Cell Signaling Technology, Danvers, MA, USA). Filters were 
incubated with the following secondary antibodies for 30' at 
room temperature: Anti‑mouse HRP‑conjugated (1:10,000; 
cat. no. A‑90‑116P); anti‑rabbit HRP‑conjugated (1:10,000; 
cat. no. A120‑108P) (both from Bethyl Laboratories, Inc., 
Montgomery, TX, USA). Signals were detected with Western 
Lightning Plus-ECL (Perkin-Elmer).
Mass spectrometry. Plasmids expressing Flag‑GLI1 (424‑1106), 
MEKK1 or empty vector were transfected in to the 293T cells 
using Lipofectamine 2000. After 24 h, the cells were washed 
with PBS and lysed in 1% NP‑40, 50 mM HEPES pH 7.5, 
150 mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM NaF, 
1 mM Na3VO4, 1 mM DTT and protease inhibitors. Lysates 
were centrifuged and the supernatants incubated with anti-Flag 
M2 agarose conjugated beads (A2220; Sigma‑Aldrich) over-
night at 4˚C. At the end of incubation, the agarose beads were 
washed extensively with lysis buffer and then with PBS. The 
immunocomplexes were eluted with 0.1 mg/ml Flag peptide, 
precipitated with 5% TCA and the pellet washed twice with 
acetone and analyzed as previously described (9,24).
MTT assay. The Med1-MB cells were treated with Nocodazole 
(0.1 µg/ml) or transfected with MEKK1 or the empty vector, using 
Lipofectamine 2000. For the transfected cells, after 2 weeks of 
selection with G418 0.8 mg/ml, stable cell lines were used for 
MTT assay. For this purpose, the cells were seeded in triplicate 
in 96‑well plates at a density of 2x104 cells/ml. At the indicated 
time‑points (24 or 48 or 72 h Fig. 9B; 48 h Fig. 9C), 10 µl of a 
5 mg/ml MTT stock solution (purchased from Sigma‑Aldrich; 
cat. no. M2128) was added to each well and the plates were 
incubated for 3 h at 37˚C. Following incubation, 100 µl of DMSO 
were added to each well to solubilize the crystals. The plates were 
shaken for 15 min and the absorbance was read with a Wallac 
Victor 2 1420 Spectrophotometer (Perkin‑Elmer) at 570 nm.
RNA interference. RNA knockdown was performed with 
pools of siRNA duplexes (50 to 100 nM) transfected into 
the NIH3T3 cells using Lipofectamine 2000. The following 
siRNA purchased from Dharmacon were used: siControl 
cat. no. D‑001206‑13‑20; siMekk1 cat. no. L‑040605‑00‑0020.
Colony formation assay. The Med1-MB cells were transfected 
using Lipofectamine 2000 as previously described (13) with a 
control vector or MEKK1. After 24 h, the cells were counted 
and equally diluted on new plates in presence of Neomycin 
(0.8 mg/ml). After 10 days, the foci were stained with Coomassie 
blue (cat. no. B0149; Sigma‑Aldrich) for 10 min at room tempera-
ture rinsed with PBS, and counted using ImageJ Software 1.50i. 
The experiments were performed 3 times in triplicate.
Statistical analysis. Statistical significance was determined 
using a paired Student's t‑test or one‑way ANOVA followed 
by Tukey's post hoc test using GraphPad Prism 6.0 software. 
A value of P<0.05 was considered to indicate a statistically 
significant difference.
Results
The kinase MEKK1 inhibits HH-GLI1 activity. We examined 
the effect of 5 different MAP3K (MEKK1, TPL2, MLK3, 
ASK1 and TAK1) on the activity of ectopically expressed 
GLI1, using a luciferase reporter vector containing 12 repeats 
of a GLI-Bs, upstream of the TK promoter (12xGLI-Luc) 
(Dr R. Tofgard, Karolinska Institute). Among the kinases 
tested, ASK1, MLK3 and MEKK1 exerted a significant inhibi-
tory effect, while the others did not markedly affect GLI1 
activity (Fig. 1A). Since the most potent effect was achieved by 
MEKK1, we focused our study on this kinase. We confirmed 
the inhibition on a different GLI‑Luc reporter, containing 8 
repeats of the GLI binding site (8xGLI‑Luc), indicating that 
the effect was specific for GLI‑Bs (Fig. 1B). The inhibition was 
dose‑dependent and was very robust at the doses of the trans-
fected plasmids as low as 5 ng (Fig. 1B). We then examined the 
effect of the ectopic expression of MEKK1 on the activity of 
GLI2, the early effector of HH signaling. As shown in Fig. 1C, 
this transcription factor was also potently inhibited by the 
kinase, suggesting the involvement of a conserved region of 
the two proteins.
To determine whether MEKK1 also has an effect on a native 
HH responsive promoter, we examined the transcriptional 
response of the PTCH1 gene, which is induced by HH signaling 
through a conserved GLI binding site in its promoter region (9). 
The overexpression of GLI1 in mouse NIH3T3 cells caused an 
increase in the endogenous PTCH1 mRNA levels, as measured 
by RT‑qPCR (Fig. 2A). Consistently, the ectopic expression of 
GLI1 led to an increase in PTCH‑Luc reporter (P1A) activity. 
In both cases, the induction achieved with the overexpression of 
GLI1 was prevented by the co‑expression of WT MEKK1, but not 
of a kinase death (KD) mutant (Fig. 2), indicating that MEKK1 
inhibition requires the catalytic activity of the protein. GLI1 and 
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MEKK1 failed to exert any significant effect on a PTCH‑Luc 
vector mutated on the GLI binding site (P1Amut) (Fig. 2B), 
demonstrating that the inhibition is specific for GLI target genes 
and cannot be attributed to effects on other promoter regions. 
To confirm the effects of endogenous MEKK1 on HH signaling, 
we performed siRNA-mediated knockdown. The ablation of the 
kinase resulted in increased basal and GLI1‑induced activity of 
a GLI-Luc reporter and of basal and Sag-induced levels of GLI1 
mRNA (Fig. 3), indicating that endogenous MEKK1 exerts 
an inhibitory effect on GLI1 activity. To further support this 
observation, we examined the effect of Nocodazole, a MEKK1 
activator (25), on HH-GLI signaling. The exposure of the cells to 
Nocodazole caused a robust decrease in GLI1-induced luciferase 
activity of a GLI‑Luc reporter (Fig. 4A) and of the Sag‑induced 
expression of GLI1 mRNA (Fig. 4B), further demonstrating the 
ability of endogenous MEKK1 to modulate the HH signaling.
MEKK1 binds and pxhosphorylates GLI1. Having observed 
that MEKK1 inhibits GLI1 activity, we first wished to deter-
mine whether this effect was related to the ability of the kinase 
to associate with this transcription factor. Immunoprecipitation 
of Flag-GLI1 revealed an association of the transcription factor 
with ectopically expressed His‑MEKK1. This binding was 
readily competed by the addition of the Flag peptide (Fig. 5A) 
in molar excess, demonstrating the specificity of the interaction.
We then examined whether MEKK1 phosphorylates GLI1, 
by co‑transfecting Flag tagged GLI1 together with MEKK1 
or its empty vector into 293T cells. As shown in Fig. 5B, 
following Flag immunoprecipitation, the band corresponding 
to GLI1 exhibited a retarded migration in the presence of 
MEKK1 compared to the control. To prove that this retarded 
band was due to GLI1 phosphorylation, we incubated the 
immunocomplex from Flag immunoprecipitation with calf 
intestinal phosphatase (CIP) and observed that the GLI1 band 
was no longer retarded by the kinase (Fig. 5C), leading us to 
conclude that MEKK1 phosphorylates GLI1.
Figure 1. Regulation of the GLI1 promoter by MEKK1. (A) 293T cells 
were co-transfected with the expression plasmid encoding Flag-GLI1 and 
expression vectors for MEKK1, TPL2, MLK3, ASK1, TAK1 or control 
vector (Flag‑pcDNA3), and a 12x‑GLI luciferase promoter reporter. Plasmid 
TK-Renilla was transfected to normalize the transfection efficiency. Data 
are expressed as the fold change of the ratio between luciferase to Renilla 
activity. (B) 293T cells were transfected with 8x‑GLI luciferase promoter 
reporter and TK Renilla plasmids and with vectors expressing Flag‑pcDNA3 
or Flag‑GLI1 and increasing amounts of MEKK1 plasmid (5, 20 and 100 ng), 
where indicated. Data are shown as the fold change of the ratio of luciferase 
reporter to Renilla activity. (C) 293T cells were co‑transfected with 8x‑GLI 
luciferase reporter and TK Renilla plasmids and Flag-GLI1 or Flag-GLI2 
expression vectors or control vector (Flag‑pcDNA3). Data are expressed as 
the fold change of the ratio between luciferase to Renilla activity. Results are 
the means ± SD of 3 independent experiments, each performed in triplicate. 
**P<0.01 and ***P<0.001 (determined by ANOVA with Tukey's post hoc test).
Figure 2. MEKK1 inhibits promoter‑specific PTCH1 transcription. (A) NIH3T3 
cells were transfected with Flag-GLI1 or control vector and MEKK1 expres-
sion plasmids. Relative expression of PTCH1 mRNA was evaluated by 
RT-qPCR. Data were normalized to HPRT mRNA levels and are expressed 
as the fold change relative to control sample. (B) 293T cells were transiently 
transfected with P1A WT and P1A mutant promoter luciferase constructs, 
and the TK Renilla encoding gene as reporters, and plasmids encoding GLI1, 
MEKK1 WT or KD or empty vector. Data are expressed as the fold change of 
the ratio between luciferase to Renilla activity. The results are the means ± SD 
of 3 independent experiments, each performed in triplicate. ***P<0.001; ns, not 
significant (calculated by ANOVA with Tukey's post hoc test).
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To elucidate which region of GLI1 is regulated by MEKK1, 
we then performed biochemical and functional analyses of 
the N‑terminal (2‑413) and C‑terminal (424‑1106) fragments 
of GLI1. Since the N-terminal region contains the GLI DNA 
binding domain, but not a transactivation domain, we used 
a chimeric construct consisting of this region fused to the 
VP16 transactivation domain (TAD) co-transfected with 
an 8xGLI‑Luc reporter. Conversely, since the C‑terminal 
region contains the TAD domain of GLI1, but not the DNA 
binding domain (DBD), we used a vector containing the 
C‑terminus fused to a Gal4 DBD together with a 5x Gal4‑Luc 
reporter (Fig. 6A) (9). The ectopic expression of MEKK1 
inhibited Gal4‑GLI1(424‑1106), but not GLI1(2‑413)‑Vp16 
activity (Fig. 6A), indicating that the MEKK1 regulation 
occurs in the C‑terminal portion. Consistently, we observed 
that MEKK1 caused a retardation of the electrophoretic migra-
tion of the C-Terminal GLI1 fragment, but did not affect the 
mobility of the N‑Terminal region (Fig. 6B). Thus, MEKK1 
binds and phosphorylates GLI1 at its C‑terminal region.
To identify the modified residue/s of GLI1 and understand 
the molecular consequences of the phosphorylation, we 
performed mass spectrometric analysis on immunoprecipi-
tated Flag‑GLI1 C‑Term in 293T cells. We observed that GLI1 
was phosphorylated in 27 residues in the presence of MEKK1, 
Figure 3. MEKK1 ablation increases HH/GLI1 activity. (A) NIH3T3 cells 
were transiently transfected with control siRNA (siCtrl, 100 nM) or Mekk1 
siRNA (siMekk1, 100 nM) and 12x‑GLI and TK Renilla luciferase reporters. 
Cells were harvested and analyzed for luciferase activity. Data are expressed 
as the fold change of the ratio between luciferase to Renilla activity. (B) GLI1 
mRNA expression levels in Sag‑treated NIH3T3 cells expressing control 
siRNA (siCtrl, 100 nM) or Mekk1 siRNA (siMekk1, 100 nM) were evaluated 
by RT‑qPCR. GLI1 mRNA levels were normalized to HPRT mRNA levels and 
expressed as fold change relative to control sample. Data are the means ± SD 
of at least 3 independent experiments, each performed in triplicate. **P<0.01 
and ***P<0.001 (determined by ANOVA with Tukey's post hoc test).
Figure 4. Pharmacological MEKK1 activation inhibits GLI1 activity. 
(A) Luciferase reporter activity in 293T cells transiently transfected with 
12x-GLI luciferase and TK Renilla reporters. Cells were treated with 
Nocodazole (1 µg/ml) for 24 h and analyzed for luciferase activity. Data are 
expressed as the fold change of the ratio between luciferase to Renilla activity. 
(B) GLI1 mRNA expression levels in Sag‑treated NIH3T3 cells exposed to 
Nocodazole (0.1 µg/ml) for 36 and 48 h. GLI1 were analyzed by RT‑qPCR 
and normalized to GAPDH mRNA levels. Results are expressed as the 
fold change relative to the control (vehicle) sample. Data are the means ± SD 
of at least 3 independent experiments, each performed in triplicate. **P<0.01 
and ***P<0.001 [calculated using the Student's t‑test (A) or ANOVA with 
Tukey's post hoc test (B)].
Figure 5. MEKK1 binds and phosphorylates GLI1. (A) 293T cells were trans-
fected with constructs encoding Flag‑GLI1 and His‑MEKK1 and cell lysates 
were immunoprecipitated with anti‑Flag antibody without or with 0.1 mg/ml 
blocking peptide. MEKK1 and GLI1 were revealed with anti MEKK1 and 
anti‑Flag antibodies, respectively. Input: 5%. (B) Western blot analysis of cel-
lular lysates from 293T cells expressing Flag‑Gli1 alone or in combination 
with His‑MEKK1. Flag‑GLI1 was revealed with anti‑Flag antibody. (C) 293T 
cells transfected with plasmids encoding Flag-GLI1 and His-MEKK1. Cell 
lysates were immunoprecipitated and immunocomplexes were incubated in 
the absence or presence of calf intestinal phosphatase (CIP).
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whereas only one residue was found phosphorylated in the 
absence of the kinase (Fig. 7). We also found that a few proteins 
co‑purified with immunoprecipitated GLI1 + MEKK1, but 
not with GLI1 alone. Mass spectrometric analysis of these 
Figure 6. MEKK1 inhibits GLI1 transcriptional activity and phosphorylates the C‑terminal region of GLI1. (A) Left panel, schematic representation of fusion 
vectors expressing GLI1(2‑413)Vp16 and 8xGLI luciferase reporter or Gal4‑GLI1(424‑1106) and 5xGal4 luciferase reporter plasmids. Right panel, luciferase 
assay on 293T cells transfected with GLI1(2‑413)Vp16 and 8xGli‑Luc or Gal4‑GLI1(424‑1106) and 5xGal4‑Luc vectors, with or without MEKK1 expression 
plasmid. Plasmid encoding TK Renilla was transfected to normalize transfection efficiency. Data are expressed as the fold change of the ratio between 
luciferase to Renilla activity. (B) Western blot analysis of immunoprecipitates from 293T cells transfected with expression vectors for Flag‑GLI1(2‑413) or 
Flag‑GLI1(424‑1106), with or without MEKK1. Flag‑GLI1 was revealed with anti‑Flag antibody. Results are expressed as the means ± SD of at least 3 inde-
pendent experiments, each performed in triplicate. ***P<0.001; ns, not significant (calculated by ANOVA with Tukey's post hoc test).
Figure 7. Phosphorylation status of GLI1 in absence or presence of MEKK1. Aminoacidic sequence of GLI1 showing phosphorylated residues (highlighted 
in red). Mass spectrometric analysis was performed on 293T cells transfected with plasmid encoding Flag‑GLI1 C‑terminal region (AA 424‑1106), with or 
without MEKK1. Cell lysates were immunoprecipitated with anti‑Flag antibody and analyzed.
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bands revealed that 14‑3‑3 ε,ζ/δ, τ were specifically detected 
in the GLI1 + MEKK1 lane (Fig. 8A, lane B). These data were 
further validated by a co‑immunoprecipitation experiment that 
revealed the association between Flag-GLI1 and endogenous 
14‑3‑3ε (Fig. 8B). Furthermore, we found that MEKK1 also 
co‑purified with immunoprecipitated GLI1 (Fig. 8A, lane B), 
confirming the previously described binding assay (Fig. 5A).
MEKK1 exerts an inhibitory effect on cultured medulloblas-
toma cells. To determine the effects of the MEKK1/GLI1 
regulation on tumor growth and viability, we performed 
colony formation and MTT assays. We utilized the Med1‑MB 
cells, a SHH medulloblastoma cell line derived from a tumor 
originated in a PTCH1+/- mouse. The mutation of the PTCH1 
gene in these cells causes an upregulation of the signaling 
pathway and hence high levels of GLI1, but not of the other 
GLIs. Thus, selective GLI1 inhibitors prevent the growth of 
these cells (19,20).
We stably transfected the Med1‑MB cells with MEKK1 or 
control vectors and analyzed cell proliferation and viability. 
As shown in Fig. 9A and B, the Med1-MB cells expressing 
MEKK1 exhibited a number of colonies and a percentage of 
viable cells which were significantly lower than those of the 
cells transfected with the control vector, indicating that this 
kinase efficiently counteracted the growth and viability of 
HH-dependent tumor cells.
We also examined the effect of the MEKK1 agonist, 
Nocodazole, on medulloblastoma cells and found that this drug 
significantly decreased the number of viable cells compared to 
the control (Fig. 9C). Collectively, these data indicate that the 
activation of MEKK1 exerts significant anticancer effects by 
inhibiting GLI1 function.
Discussion
HH signaling is found aberrantly activated in a number 
of tumors and is considered an attractive target for cancer 
therapy (26). The limited efficacy of the SMO inhibitor, 
Vismodegib, has prompted efforts to identify novel drugs with 
the ability to directly target the GLI transcription factors or 
GLI‑regulated pathways.
In this study, we provide evidence that the kinase MEKK1 
has the ability to bind and promote GLI1 phosphorylation, 
resulting in inhibition of its activity. MEKK1 is a member 
of the MAP3K family, the most upstream components of the 
mitogen‑activated protein kinase (MAPK) phosphorylated 
modules, consisting of MAPK, MAPK kinase (MKK) and 
MAPK kinase kinase (MKKK) (27). MKKKs phosphorylate 
and activate MKKs, which in turn phosphorylate and activate 
MAPKs. Twenty different MAP3Ks have been characterized 
and each of these is regulated by various cues, such as growth 
factors, cytokines, antigens, stress insults, changes in extracel-
lular matrix and cell-cell contacts.
MEKK1 is a 196 kDa protein that activates both the JNK 
and ERK pathways, although JNK appears to be preferen-
tially regulated. MEKK1 is activated by a variety of stimuli, 
including growth factors, microtubule disruption, heat shock, 
hypermolarity and UV irradiation (28). Previous studies 
Figure 8. (A) Left panel, Coomassie‑blue stained SDS‑PAGE gel, showing proteins associated to Flag‑GLI1(424‑1106), in the absence or presence of MEKK1 
in 293T cells. Lane A, proteins associated with Flag‑GLI1(424‑1106); lane B, proteins associated with Flag‑GLI1(424‑1106) + MEKK1. Numbered black 
arrows indicate bands cut out from the gel and processed. Right panel, mass spectrometry results for the selected gel bands. (B) Co‑immunoprecipitation 
assay of Flag‑GLI1 with endogenous 14‑3‑3ε proteins in 293T cells, with or without MEKK1. Lysates were immunoprecipitated with anti‑Flag antibody and 
endogenous 14‑3‑3ε proteins binding is shown.
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have documented a crosstalk between the HH and MAPK 
cascades (29) and its role in various tumors, including 
cancers of the skin, gastrointestinal, pancreas, liver, breast 
and brain (30).
It has been demonstrated that a positive synergy exists 
between the two signaling pathways, mainly mediated by 
ERK1/2 kinases, which have been shown to induce GLI1 
phosphorylation and activation, thus implying that a proper 
combination of specific pathway inhibitors could be a possible 
therapeutic options for these type of tumors (28). In contrast 
to these observations, in this study, we provide evidence that 
MEKK1, which has the ability to activate both ERK and JNK, 
inhibits GLI1 function through multiple phosphorylation 
events, occurring at the C-terminal domain of the transcrip-
tion factor. Mass spectrometric analysis revealed almost 
30 sites in the C‑term of GLI1 were phosphorylated in cells 
expressing MEKK1. Unfortunately, our attempts to identify 
a phosphorylation‑defective mutant failed and we could not 
mutagenize all the modified residues, due to stability issues 
and generation of unreliable data. However, we observed that 
upon MEKK1 phosphorylation, GLI1 associated with 14‑3‑3 
proteins, suggesting that this binding may be responsible, at 
least in part, for the observed inhibitory effect. In support 
of this hypothesis, a previous study described an association 
between GLI and 14‑3‑3 upon PKA phosphorylation that was 
associated by transcriptional inhibition (31), although the 
underlying mechanism was not fully elucidated.
In addition to its kinase activity, it has been observed 
that MEKK1 may also ubiquitylate some substrates such 
as c‑JUN and promote their degradation (32), suggesting 
that a proteolytic‑mediated effect could also account for the 
observed GLI1 inhibition. However, the steady state levels of 
GLI1 do not appear reduced in the presence of this kinase, 
thus ruling out degradation‑dependent mechanisms. Recently 
it has been described that two other mitogen-activated protein 
kinase kinase kinase (MAP3Ks), MEKK2 and MEKK3, play 
a critical role in regulating HH signaling. MEKK2/MEKK3 
are conserved for the 55% in the amino‑acid sequence and 
95% in the kinase domain, both are co‑expressed in many 
cell type and they share substrate specificity (16). MEKK2/3 
are activated in response to the FGF signaling and directly 
phosphorylates GLI1 resulting in the suppression of GLI1 
transcriptional activity and the suppression of HH‑dependent 
medulloblastoma tumor cell growth (16). In contrast to these 
findings, we did not observe an involvement of MEKK1 in 
the response to FGF stimulation (data not shown), indicating 
the differential recruitment of these MAP3Ks in response to 
various cues.
Finally, a relevant finding of this study was the significant 
antitumor effect of ectopically expressed MEKK1 observed in 
medulloblastoma cells. This evidence suggests that MEKK1 
can be now included among the druggable targets with the 
ability to turn off HH signaling at a post‑receptor level in 
tumors. The ability of Nocodazole to inhibit HH signaling 
Figure 9. MEKK1 counteracts in vitro medulloblastoma cells growth and viability. (A) Colony formation assay on Med1‑MB cells stably transfected with 
expression plasmids encoding MEKK1 or empty vector. Left panel, colonies were quantified with ImageJ software (Version 1.50i), using 4 images per dish. 
The bar graph represents the average of three biological replicates. Right, representative colony formation assay. (B) Left panel, MTT assay measuring cell 
proliferation activity of Med1‑MB cells expressing MEKK1 or control plasmids at 24 h, 48 h and 72 h in each group. Right panel, growth curve on Med1‑MB 
cells expressing MEKK1 or empty vector. (C) MTT assay on Med1‑MB cells treated with Nocodazole (0.1 µg/ml) for 48 h. Results are expressed as the 
means ± SD of 3 independent experiments, each performed in triplicate. ***P<0.001 and ****P<0.0001 [calculated by a Student's t‑test (A and C) or ANOVA 
with Tukey's post hoc test (B)].
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and to counteract SHH‑MB growth supports this hypothesis 
and opens the door to future studies aimed at analyzing the 
potential of Nocodazole and other MEKK1 agonists as novel 
therapeutic options for this type of malignancies.
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